your search: Sales
Relevance of hit 2% back to search result index | New search

Consolidated Income Statement

XLS

 

 

 

 

 

€ million

Q3 – 2013

Q3 – 2012

Jan.–Sept.
2013

Jan.–Sept.
2012

Sales

2,659.5

2,721.7

8,063.8

8,028.7

Royalty, license and commission income

92.3

119.4

289.6

309.4

Total revenues

2,751.8

2,841.0

8,353.4

8,338.1

 

 

 

 

 

Cost of sales

–723.4

–787.6

–2,215.3

–2,344.1

Gross profit

2,028.4

2,053.4

6,138.0

5,994.0

 

 

 

 

 

Marketing and selling expenses

–560.1

–598.0

–1,744.7

–1,801.8

Royalty, license and commission expenses

–144.4

–161.6

–437.2

–433.4

Administration expenses

–136.7

–141.6

–407.0

–420.6

Other operating expenses and income

–128.4

–245.1

–428.2

–878.4

Research and development

–379.3

–370.8

–1,159.1

–1,156.5

Amortization of intangible assets

–197.7

–218.2

–616.6

–651.8

Investment result

1.4

0.5

Operating result (EBIT)

481.8

318.1

1,346.6

651.9

 

 

 

 

 

Financial result

–51.9

–58.2

–159.1

–193.9

Profit before income tax

430.0

260.0

1,187.5

458.0

 

 

 

 

 

Income tax

–87.4

–71.3

–259.9

–154.7

Profit after tax

342.5

188.7

927.6

303.3

 

 

 

 

 

of which attributable to Merck KGaA shareholders (net income)

339.6

185.5

921.6

294.9

of which non-controlling interest

3.0

3.2

6.0

8.3

 

 

 

 

 

Earnings per share (in €)

 

 

 

 

basic

1.56

0.85

4.24

1.36

diluted

1.56

0.85

4.24

1.36